JP2007512299A

JP2007512299A - 呼吸器系疾患の処置に有用な１−酢酸−インドール、−インダゾールおよび−ベンズイミダゾール誘導体

呼吸器系疾患の処置に有用な１−酢酸−インドール、−インダゾールおよび−ベンズイミダゾール誘導体 Download PDF

Info

Publication number: JP2007512299A
Authority: JP; Japan
Prior art keywords: acetic acid; alkyl; pyrrolo; pyridine; methyl
Prior art date: 2003-11-26
Legal status : Pending

Application number

JP2006540603A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007512299A5 (https=

Inventor

ロジャー・ビクター・ボナート

ルクサナ・タスニーム・モハンメド

サイモン・ティーグ

Current Assignee

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date

2003-11-26

Filing date

2004-11-24

Publication date

2007-05-17

2004-11-24 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2007-05-17 Publication of JP2007512299A publication Critical patent/JP2007512299A/ja

2007-12-06 Publication of JP2007512299A5 publication Critical patent/JP2007512299A5/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 19
208000023504 respiratory system disease Diseases 0.000 title abstract description 4
229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 145
-1 3- (7-chloro-4-quinolinyl) -2-methyl-1H-pyrrolo [2,3-b] pyridine-1-acetic acid sodium salt Chemical compound 0.000 claims description 40
238000000034 method Methods 0.000 claims description 33
150000003839 salts Chemical class 0.000 claims description 30
125000003118 aryl group Chemical group 0.000 claims description 27
125000000217 alkyl group Chemical group 0.000 claims description 26
229910052757 nitrogen Inorganic materials 0.000 claims description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
201000010099 disease Diseases 0.000 claims description 22
125000005843 halogen group Chemical group 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 18
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 16
125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 13
125000001072 heteroaryl group Chemical group 0.000 claims description 13
208000006673 asthma Diseases 0.000 claims description 12
150000002367 halogens Chemical class 0.000 claims description 12
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
239000011593 sulfur Substances 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 9
229910052799 carbon Inorganic materials 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
206010039083 rhinitis Diseases 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
HWCXKAZEDDLUKC-UHFFFAOYSA-N 2-(4-iodo-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C12=C(I)C=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=CC=C12 HWCXKAZEDDLUKC-UHFFFAOYSA-N 0.000 claims description 6
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
125000000623 heterocyclic group Chemical group 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
GTPMZKSXYFJDBT-UHFFFAOYSA-N 2-(5-cyano-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C12=CC(C#N)=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=CC=C12 GTPMZKSXYFJDBT-UHFFFAOYSA-N 0.000 claims description 5
XCGNXVPVHVVNKB-UHFFFAOYSA-N 2-(5-methyl-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C1=CC=C2C(C3=NN(CC(O)=O)C4=CC=C(C=C43)C)=CC=NC2=C1 XCGNXVPVHVVNKB-UHFFFAOYSA-N 0.000 claims description 5
NMAWECDVPZADIN-UHFFFAOYSA-N 2-[2,5-dimethyl-3-(4-methylsulfonylphenyl)sulfanylpyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 NMAWECDVPZADIN-UHFFFAOYSA-N 0.000 claims description 5
KHUZDGNSFATQCD-UHFFFAOYSA-N 2-[2,5-dimethyl-3-[(4-methylsulfonylcyclohexa-2,4-dien-1-yl)methyl]pyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1CC1CC=C(S(C)(=O)=O)C=C1 KHUZDGNSFATQCD-UHFFFAOYSA-N 0.000 claims description 5
AYDMUJOILOMOQY-UHFFFAOYSA-N 2-[3-(4-chlorocyclohexa-2,4-dien-1-yl)sulfanyl-2,5-dimethylpyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1SC1CC=C(Cl)C=C1 AYDMUJOILOMOQY-UHFFFAOYSA-N 0.000 claims description 5
JHOIZLRSVITTFP-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)sulfanyl-2-methyl-4-phenylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(C=3C=CC=CC=3)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 JHOIZLRSVITTFP-UHFFFAOYSA-N 0.000 claims description 5
JXCPHAXLKGDHBC-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)sulfanyl-5-iodoindazol-1-yl]acetic acid Chemical compound C12=CC(I)=CC=C2N(CC(=O)O)N=C1SC1=CC=C(Cl)C=C1 JXCPHAXLKGDHBC-UHFFFAOYSA-N 0.000 claims description 5
JBBXNLYCRGAXTQ-UHFFFAOYSA-N 2-[3-(6-fluoroquinolin-4-yl)-4-(trifluoromethyl)indazol-1-yl]acetic acid Chemical compound C12=C(C(F)(F)F)C=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=C(F)C=C12 JBBXNLYCRGAXTQ-UHFFFAOYSA-N 0.000 claims description 5
XEYDGQLGRXJVCH-UHFFFAOYSA-N 2-[4-chloro-3-(4-chlorophenyl)sulfanyl-2-methylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(Cl)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 XEYDGQLGRXJVCH-UHFFFAOYSA-N 0.000 claims description 5
IFGOUISYCKVYNY-UHFFFAOYSA-N 2-[2-methyl-3-(4-methylsulfonylphenyl)sulfanyl-4-phenylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(C=3C=CC=CC=3)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 IFGOUISYCKVYNY-UHFFFAOYSA-N 0.000 claims description 4
CPJNKMYTZVMKCW-UHFFFAOYSA-N 2-[4-chloro-2-methyl-3-(4-methylsulfonylphenyl)sulfanylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(Cl)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 CPJNKMYTZVMKCW-UHFFFAOYSA-N 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims description 4
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims description 4
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
239000000126 substance Substances 0.000 abstract description 5
150000002475 indoles Chemical class 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
239000000047 product Substances 0.000 description 34
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
235000019439 ethyl acetate Nutrition 0.000 description 20
239000003112 inhibitor Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 19
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
238000004949 mass spectrometry Methods 0.000 description 16
239000000243 solution Substances 0.000 description 16
239000000377 silicon dioxide Substances 0.000 description 15
238000004587 chromatography analysis Methods 0.000 description 14
239000012453 solvate Substances 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
238000013459 approach Methods 0.000 description 10
229960005419 nitrogen Drugs 0.000 description 10
239000007787 solid Substances 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
229940079593 drug Drugs 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000012044 organic layer Substances 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
201000011510 cancer Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
208000011580 syndromic disease Diseases 0.000 description 7
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
239000011324 bead Substances 0.000 description 6
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
201000004624 Dermatitis Diseases 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000012267 brine Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
239000002904 solvent Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
206010047115 Vasculitis Diseases 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
229940111134 coxibs Drugs 0.000 description 4
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
201000008482 osteoarthritis Diseases 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
201000010105 allergic rhinitis Diseases 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
239000011539 homogenization buffer Substances 0.000 description 3
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
239000012071 phase Substances 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
150000003873 salicylate salts Chemical class 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
MMSNEKOTSJRTRI-LLVKDONJSA-N 1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound S1C(C#C[C@@H](C)N(O)C(N)=O)=CC=C1CC1=CC=C(F)C=C1 MMSNEKOTSJRTRI-LLVKDONJSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
ZIXXRXGPBFMPFD-UHFFFAOYSA-N 1-chloro-4-[(4-chlorophenyl)disulfanyl]benzene Chemical compound C1=CC(Cl)=CC=C1SSC1=CC=C(Cl)C=C1 ZIXXRXGPBFMPFD-UHFFFAOYSA-N 0.000 description 2
AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
ARZAHIJXHOIQLV-UHFFFAOYSA-N 2-[3-(7-chloroquinolin-4-yl)-5-methyl-2-oxobenzimidazol-1-yl]acetic acid Chemical compound ClC1=CC=C2C(N3C(=O)N(CC(O)=O)C4=CC=C(C=C43)C)=CC=NC2=C1 ARZAHIJXHOIQLV-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
208000006820 Arthralgia Diseases 0.000 description 2
102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000008035 Back Pain Diseases 0.000 description 2
0 C*C1(C2CCCCCC2)N**NC1(*(*)CO)C1CCCCCCC1 Chemical compound C*C1(C2CCCCCC2)N**NC1(*(*)CO)C1CCCCCCC1 0.000 description 2
102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
102000009410 Chemokine receptor Human genes 0.000 description 2
108050000299 Chemokine receptor Proteins 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102100027995 Collagenase 3 Human genes 0.000 description 2
229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000007465 Giant cell arteritis Diseases 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000014429 Insulin-like growth factor Human genes 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
208000008930 Low Back Pain Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
206010039085 Rhinitis allergic Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
102100030416 Stromelysin-1 Human genes 0.000 description 2
102100028848 Stromelysin-2 Human genes 0.000 description 2
102100028847 Stromelysin-3 Human genes 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229960001671 azapropazone Drugs 0.000 description 2
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
230000009400 cancer invasion Effects 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
229960002023 chloroprocaine Drugs 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
201000003146 cystitis Diseases 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
229940043237 diethanolamine Drugs 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
229950004203 droloxifene Drugs 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229960001433 erlotinib Drugs 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
229940031098 ethanolamine Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000284 extract Substances 0.000 description 2
229960001419 fenoprofen Drugs 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
229960003194 meglumine Drugs 0.000 description 2
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229960002657 orciprenaline Drugs 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
208000012111 paraneoplastic syndrome Diseases 0.000 description 2
235000019371 penicillin G benzathine Nutrition 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
229960002702 piroxicam Drugs 0.000 description 2
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
201000005671 spondyloarthropathy Diseases 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
206010043207 temporal arteritis Diseases 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229960000281 trometamol Drugs 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
229940116269 uric acid Drugs 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
HQJDKQMEMMLYOV-UHFFFAOYSA-N (2-fluoro-5-methylphenyl)-quinolin-4-ylmethanol Chemical compound CC1=CC=C(F)C(C(O)C=2C3=CC=CC=C3N=CC=2)=C1 HQJDKQMEMMLYOV-UHFFFAOYSA-N 0.000 description 1
GOZSZTXONJMJHG-UHFFFAOYSA-N (2-fluoro-6-iodophenyl)-quinolin-4-ylmethanol Chemical compound C=1C=NC2=CC=CC=C2C=1C(O)C1=C(F)C=CC=C1I GOZSZTXONJMJHG-UHFFFAOYSA-N 0.000 description 1
DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 1
CKZUQJICXZZBHC-UHFFFAOYSA-N (6-fluoroquinolin-4-yl)-[2-fluoro-6-(trifluoromethyl)phenyl]methanone Chemical compound C12=CC(F)=CC=C2N=CC=C1C(=O)C1=C(F)C=CC=C1C(F)(F)F CKZUQJICXZZBHC-UHFFFAOYSA-N 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
HGKPAXHJTMHWAH-UHFFFAOYSA-N 1-(bromomethyl)-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(CBr)C=C1 HGKPAXHJTMHWAH-UHFFFAOYSA-N 0.000 description 1
OLZHFFKRBCZHHT-SNVBAGLBSA-N 1-[(2r)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound O1C(C#C[C@@H](C)N(O)C(N)=O)=CC=C1OC1=CC=C(F)C=C1 OLZHFFKRBCZHHT-SNVBAGLBSA-N 0.000 description 1
MWXPQCKCKPYBDR-UHFFFAOYSA-N 1-[4-[3-(4-fluorophenoxy)phenyl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound NC(=O)N(O)C(C)C#CC1=CC=CC(OC=2C=CC(F)=CC=2)=C1 MWXPQCKCKPYBDR-UHFFFAOYSA-N 0.000 description 1
UUORGSXWPOMXJJ-UHFFFAOYSA-N 1-[azido(ethyl)phosphoryl]ethane Chemical compound CCP(=O)(CC)N=[N+]=[N-] UUORGSXWPOMXJJ-UHFFFAOYSA-N 0.000 description 1
VSKSBSORLCDRHS-UHFFFAOYSA-N 1-fluoro-3-iodobenzene Chemical compound FC1=CC=CC(I)=C1 VSKSBSORLCDRHS-UHFFFAOYSA-N 0.000 description 1
VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
XXYVGTWDKQHQOG-UHFFFAOYSA-N 1-methylsulfonyl-4-[(4-methylsulfonylphenyl)disulfanyl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1SSC1=CC=C(S(C)(=O)=O)C=C1 XXYVGTWDKQHQOG-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
VSRXYLYXIXYEST-KZTWKYQFSA-N 13,14-dihydro-15-ketoprostaglandin D2 Chemical compound CCCCCC(=O)CC[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O VSRXYLYXIXYEST-KZTWKYQFSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
QQSROFSUDGOIHB-UHFFFAOYSA-N 2,5-dimethyl-3-(4-methylsulfonylphenyl)sulfanyl-1h-pyrrolo[3,2-b]pyridine Chemical compound CC=1NC2=CC=C(C)N=C2C=1SC1=CC=C(S(C)(=O)=O)C=C1 QQSROFSUDGOIHB-UHFFFAOYSA-N 0.000 description 1
NALOLPHESHBMOP-UHFFFAOYSA-N 2,5-dimethyl-3-[(4-methylsulfonylphenyl)methyl]-1h-pyrrolo[3,2-b]pyridine Chemical compound CC=1NC2=CC=C(C)N=C2C=1CC1=CC=C(S(C)(=O)=O)C=C1 NALOLPHESHBMOP-UHFFFAOYSA-N 0.000 description 1
JALUUBQFLPUJMY-UHFFFAOYSA-N 2-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 JALUUBQFLPUJMY-UHFFFAOYSA-N 0.000 description 1
JBVZPWQVGREBOT-UHFFFAOYSA-N 2-[(7-chloroquinolin-4-yl)amino]-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 JBVZPWQVGREBOT-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
RPGKFFKUTVJVPY-UHFFFAOYSA-N 2-amino-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1 RPGKFFKUTVJVPY-UHFFFAOYSA-N 0.000 description 1
QLRKALMVPCQTMU-UHFFFAOYSA-N 2-bromo-1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C(Br)=C1 QLRKALMVPCQTMU-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
PXIQAYIICSUMKF-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfanyl-2-methyl-4-phenyl-1h-pyrrolo[3,2-c]pyridine Chemical compound C=12C(SC=3C=CC(Cl)=CC=3)=C(C)NC2=CC=NC=1C1=CC=CC=C1 PXIQAYIICSUMKF-UHFFFAOYSA-N 0.000 description 1
TVBJVNADWRAFAO-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfanyl-5-iodo-1h-indazole Chemical compound C1=CC(Cl)=CC=C1SC1=NNC2=CC=C(I)C=C12 TVBJVNADWRAFAO-UHFFFAOYSA-N 0.000 description 1
MRXMURPGQMBNJS-UHFFFAOYSA-N 3-(7-chloroquinolin-4-yl)-5-methyl-1h-benzimidazol-2-one Chemical compound ClC1=CC=C2C(N3C(=O)NC4=CC=C(C=C43)C)=CC=NC2=C1 MRXMURPGQMBNJS-UHFFFAOYSA-N 0.000 description 1
BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
UMZFWSPCVUSXHT-UHFFFAOYSA-N 3-quinolin-4-yl-1h-indazole-5-carbonitrile Chemical compound C1=CC=C2C(C3=NNC4=CC=C(C=C43)C#N)=CC=NC2=C1 UMZFWSPCVUSXHT-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
VKGQWFHDCWYYNE-UHFFFAOYSA-N 4-(4-iodo-1h-indazol-3-yl)quinoline Chemical compound C1=CC=C2C(C3=NNC=4C=CC=C(C3=4)I)=CC=NC2=C1 VKGQWFHDCWYYNE-UHFFFAOYSA-N 0.000 description 1
MBLJFKQACMILLC-UHFFFAOYSA-N 4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidamide Chemical compound C=1C=C(OCC=2C=C(COC=3C=CC(=CC=3)C(N)=N)C=CC=2)C=CC=1C(C)(C)C1=CC=C(O)C=C1 MBLJFKQACMILLC-UHFFFAOYSA-N 0.000 description 1
QBKXYSXQKRNVRQ-UHFFFAOYSA-N 4-bromo-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1Br QBKXYSXQKRNVRQ-UHFFFAOYSA-N 0.000 description 1
GZRNWDOHXHJRDZ-UHFFFAOYSA-N 4-chloro-2-methyl-1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC(C)=CC2=C1Cl GZRNWDOHXHJRDZ-UHFFFAOYSA-N 0.000 description 1
QPFXQJHJULLPCU-UHFFFAOYSA-N 4-chloro-3-(4-chlorophenyl)sulfanyl-2-methyl-1h-pyrrolo[3,2-c]pyridine Chemical compound CC=1NC2=CC=NC(Cl)=C2C=1SC1=CC=C(Cl)C=C1 QPFXQJHJULLPCU-UHFFFAOYSA-N 0.000 description 1
KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
LMEGTVDIZJQBFQ-UHFFFAOYSA-N 4-fluoro-3-(quinoline-4-carbonyl)benzonitrile Chemical compound FC1=CC=C(C#N)C=C1C(=O)C1=CC=NC2=CC=CC=C12 LMEGTVDIZJQBFQ-UHFFFAOYSA-N 0.000 description 1
SPURNQVPNMCGDK-UHFFFAOYSA-N 4-fluoro-3-[hydroxy(quinolin-4-yl)methyl]benzonitrile Chemical compound C=1C=NC2=CC=CC=C2C=1C(O)C1=CC(C#N)=CC=C1F SPURNQVPNMCGDK-UHFFFAOYSA-N 0.000 description 1
102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
JQLIRVDYEDHUNH-UHFFFAOYSA-N 6-fluoro-4-[4-(trifluoromethyl)-1h-indazol-3-yl]quinoline Chemical compound C1=CC(C(F)(F)F)=C2C(C3=CC=NC4=CC=C(C=C43)F)=NNC2=C1 JQLIRVDYEDHUNH-UHFFFAOYSA-N 0.000 description 1
RMDCSDVIVXJELQ-UHFFFAOYSA-N 6-fluoroquinoline Chemical compound N1=CC=CC2=CC(F)=CC=C21 RMDCSDVIVXJELQ-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
IXJCHVMUTFCRBH-SDUHDBOFSA-N 7-[(1r,2s,3e,5z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCC\C=C/C=C/[C@@H]([C@H](O)C=1C=C(C=CC=1)C(F)(F)F)SC1=CC=C2C(=O)C=C(C(O)=O)OC2=C1 IXJCHVMUTFCRBH-SDUHDBOFSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
208000035939 Alveolitis allergic Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229940124810 Alzheimer's drug Drugs 0.000 description 1
102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
206010068172 Anal pruritus Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
206010002921 Aortitis Diseases 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
206010053555 Arthritis bacterial Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
102000036365 BRCA1 Human genes 0.000 description 1
108700020463 BRCA1 Proteins 0.000 description 1
101150072950 BRCA1 gene Proteins 0.000 description 1
102000052609 BRCA2 Human genes 0.000 description 1
108700020462 BRCA2 Proteins 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
101150008921 Brca2 gene Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
241001260012 Bursa Species 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
229940124003 CRTH2 antagonist Drugs 0.000 description 1
108010061298 CXCR5 Receptors Proteins 0.000 description 1
102000012001 CXCR5 Receptors Human genes 0.000 description 1
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
101150065984 Comp gene Proteins 0.000 description 1
208000009248 Congenital Hip Dislocation Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
208000019872 Drug Eruptions Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229940122858 Elastase inhibitor Drugs 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
206010016207 Familial Mediterranean fever Diseases 0.000 description 1
208000027445 Farmer Lung Diseases 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000032678 Fixed drug eruption Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102000011652 Formyl peptide receptors Human genes 0.000 description 1
108010076288 Formyl peptide receptors Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000005232 Glossitis Diseases 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
208000003695 Histiocytic Necrotizing Lymphadenitis Diseases 0.000 description 1
206010069070 Histiocytic necrotising lymphadenitis Diseases 0.000 description 1
101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 1
101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
102100020873 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
241000764238 Isis Species 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
208000015282 Kikuchi-Fujimoto disease Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
208000000185 Localized scleroderma Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
101150014058 MMP1 gene Proteins 0.000 description 1
102100027998 Macrophage metalloelastase Human genes 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000000592 Nasal Polyps Diseases 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
108030001564 Neutrophil collagenases Proteins 0.000 description 1
102000056189 Neutrophil collagenases Human genes 0.000 description 1
102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
102000004459 Nitroreductase Human genes 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
241001420836 Ophthalmitis Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
102000015094 Paraproteins Human genes 0.000 description 1
108010064255 Paraproteins Proteins 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
108050000258 Prostaglandin D receptors Proteins 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037457 Pulmonary vasculitis Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039094 Rhinitis perennial Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
108050005271 Stromelysin-3 Proteins 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
208000010265 Sweet syndrome Diseases 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000003141 Tachykinin Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
229940122598 Tryptase inhibitor Drugs 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000008526 Wells syndrome Diseases 0.000 description 1
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
QQHDLQDOUOASOX-UHFFFAOYSA-N acetic acid;1h-indazole Chemical class CC(O)=O.C1=CC=C2C=NNC2=C1 QQHDLQDOUOASOX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
108010003059 aggrecanase Proteins 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
206010068168 androgenetic alopecia Diseases 0.000 description 1
201000002996 androgenic alopecia Diseases 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000007131 anti Alzheimer effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002137 anti-vascular effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960002708 antigout preparations Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
229960005207 auranofin Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960004574 azelastine Drugs 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical class NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
229960002529 benzbromarone Drugs 0.000 description 1
WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
208000010217 blepharitis Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
229940043256 calcium pyrophosphate Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
229950002826 canertinib Drugs 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
208000010353 central nervous system vasculitis Diseases 0.000 description 1
201000002676 cerebral atherosclerosis Diseases 0.000 description 1
229960003115 certolizumab pegol Drugs 0.000 description 1
229960001803 cetirizine Drugs 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
238000012822 chemical development Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
208000017760 chronic graft versus host disease Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
201000009151 chronic rhinitis Diseases 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
108700004333 collagenase 1 Proteins 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
229960005537 combretastatin A-4 Drugs 0.000 description 1
HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940109248 cromoglycate Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
229960001271 desloratadine Drugs 0.000 description 1
208000014906 developmental dysplasia of the hip Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019821 dicalcium diphosphate Nutrition 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960003530 donepezil Drugs 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003602 elastase inhibitor Substances 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
SBVYURPQULDJTI-UHFFFAOYSA-N ethyl n-[amino-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]methylidene]carbamate Chemical compound C1=CC(C(=N)NC(=O)OCC)=CC=C1OCC1=CC=CC(COC=2C=CC(=CC=2)C(C)(C)C=2C=CC(O)=CC=2)=C1 SBVYURPQULDJTI-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
229960004396 famciclovir Drugs 0.000 description 1
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
208000022195 farmer lung disease Diseases 0.000 description 1
229950002170 fenleuton Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229960003592 fexofenadine Drugs 0.000 description 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
208000012587 fixed pigmented erythema Diseases 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
150000005699 fluoropyrimidines Chemical class 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000938 histamine H1 antagonist Substances 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
229940018991 hyalgan Drugs 0.000 description 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
108091006086 inhibitor proteins Proteins 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
229950000831 iralukast Drugs 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
229960002367 lasofoxifene Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960003088 loratadine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
208000008585 mastocytosis Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
229960001952 metrifonate Drugs 0.000 description 1
206010063344 microscopic polyangiitis Diseases 0.000 description 1
229940101972 mirapex Drugs 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
RVXKHAITGKBBAC-SFHVURJKSA-N n-[(1s)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine Chemical compound C([C@H](NC=1OC2=CC=C(C=C2N=1)C)C=1N=CC=CC=1)C1CCCCC1 RVXKHAITGKBBAC-SFHVURJKSA-N 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
208000000288 neurosarcoidosis Diseases 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
108020001162 nitroreductase Proteins 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229950010666 ontazolast Drugs 0.000 description 1
230000001009 osteoporotic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229960001609 oxitropium bromide Drugs 0.000 description 1
LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
208000010403 panophthalmitis Diseases 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
208000022719 perennial allergic rhinitis Diseases 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
208000030062 persistent idiopathic facial pain Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
YKGCCFHSXQHWIG-UHFFFAOYSA-N phenothiazin-3-one Chemical compound C1=CC=C2SC3=CC(=O)C=CC3=NC2=C1 YKGCCFHSXQHWIG-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
208000017983 photosensitivity disease Diseases 0.000 description 1
RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
229960004633 pirenzepine Drugs 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
150000004672 propanoic acids Chemical class 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940095574 propionic acid Drugs 0.000 description 1
MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical class C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
ALQUTEKNDPODSS-UHFFFAOYSA-N quinoline-4-carbaldehyde-oxime Natural products C1=CC=C2C(C=NO)=CC=NC2=C1 ALQUTEKNDPODSS-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
229960000245 rasagiline Drugs 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
229940113775 requip Drugs 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
201000003646 skin sarcoidosis Diseases 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
YPURUCMVRRNPHJ-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C12=CC=C(OCC=3N=C4C=CC=CC4=CC=3)C=C2C(SC(C)(C)C)=C(CC(C)(C)C([O-])=O)N1CC1=CC=C(Cl)C=C1 YPURUCMVRRNPHJ-UHFFFAOYSA-M 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
229960003329 sulfinpyrazone Drugs 0.000 description 1
MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
230000008409 synovial inflammation Effects 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
108060008037 tachykinin Proteins 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229950011332 talnetant Drugs 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229940000238 tasmar Drugs 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
229960001674 tegafur Drugs 0.000 description 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
229950004351 telenzepine Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
DTVUOCBZVJRFCC-UHFFFAOYSA-N tert-butyl n-(2-chloro-3-prop-1-ynylpyridin-4-yl)carbamate Chemical compound CC#CC1=C(Cl)N=CC=C1NC(=O)OC(C)(C)C DTVUOCBZVJRFCC-UHFFFAOYSA-N 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
229960000257 tiotropium bromide Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
238000001665 trituration Methods 0.000 description 1
239000002750 tryptase inhibitor Substances 0.000 description 1
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
208000001319 vasomotor rhinitis Diseases 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229940023080 viracept Drugs 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1
208000010484 vulvovaginitis Diseases 0.000 description 1
239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
229960004764 zafirlukast Drugs 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
229960005332 zileuton Drugs 0.000 description 1